key: cord-0973652-igxwuds7
authors: Tobaiqy, M.; Alhumaid, S.; Al Mutair, A.
title: Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis
date: 2020-06-19
journal: nan
DOI: 10.1101/2020.06.16.20133298
sha: 31ba44f32d9e5793e847cd3b125698100eeababb
doc_id: 973652
cord_uid: igxwuds7

Background Since the emergence of COVID-19, the world has been desperate to find effective therapeutics and vaccinations to treat hundreds of thousands of affected patients and to suppress the spread of this global pandemic. Lopinavir-ritonavir (LPV/RTV) is an HIV antiviral combination that has been considered for treatment of this disease. Aim of the study This systematic review and meta-analysis aimed to assess the efficacy and safety of lopinavir/ritonavir in COVID-19 patients in the extant published research. A systematic review protocol was developed based on PRISMA-P and the PRISMA statement. Published English and non-English articles written since December 1, 2019 were selected for review from 8 electronic databases. Readily accessible full articles (cohort studies and clinical trials) which specifically mentioned lopinavir/ritonavir and patients with lab-confirmed SARS-CoV-2 or COVOID-19 of any age were included. Three researchers separately evaluated the bias in the reported articles. We conducted a systematic review and meta-analysis with the objective of evaluation of the safety and efficacy of LPV/RTV alone or in combination with other drugs with regard to time to becoming PCR negative, time to body temperature normalization and cough relief, radiological progression, and safety. Review Manager (RevMan) was used to conduct all statistical analyses and generate the forest plots. Meta-analyses were performed using the Mantel Hazel method or the inverse variance method for dichotomous data and continuous data respectively. Results Non-duplicate articles (n=76) were evaluated for possible inclusion. A consensus was reached to select 29 articles for full-text screening, only 11 articles comprised 1,192 patients were included in this study, and six of which were included for meta-analysis. In terms of virological cure (PCR negative), three studies reported less time in days to achieve a virological cure for LPV/RTV arm relative to no antiviral therapy (conventional) (mean difference = -0.81 day; 95% CI, -4.44 to 2.81; P = 0.007, I2 = 80%). However, the overall effect was not significant (P = 0.66). When comparing LPV/RTV arm to umifenovir arm, a favorable affect was observed for umifenovir arm, but not statically significant (mean difference = 0.95 day; 95% CI, -1.11 to 3.01; P = 0.09, I2 = 58%). In terms of time to body normalization and cough relief (clinical cure), two studies reported on time to temperature normalization with no significant effect of LPV/RTV (n = 93) versus umifenovir (n = 71) arm), (OR = 0.87 day; 95% CI, 0.42 to 1.78; (P = 0.70), I2 = 0%), or alleviation of cough duration (p = 0.69). In terms of CT evidence of radiological progression of pneumonia/lung damage, treatment with lopinavir/ritonavir resulted in no significant decrease in the radiological progression (OR = 0.80; 95% CI, 0.42 to 1.54; P = 0.59, I2 = 81%), In terms of safety, a greater number of adverse events were reported for lopinavir/ritonavir (n=45) relative to the umifenovir arm (n=14) and conventional treatments (n=10 ), P = 0.004, 0,0007, respectively Conclusions The small number of studies included in this systematic review and meta-analysis study did not reveal any statistically significant advantage in efficacy of lopinavir-ritonavir in COVID-19 patients, over conventional or other antiviral treatments. This result might not reflect the actual evidence.

Readily accessible full articles (cohort studies and clinical trials) which specifically mentioned lopinavir/ritonavir and patients with lab-confirmed SARS-CoV-2 or COVOID-19 of any age were included. Three researchers separately evaluated the bias in the reported articles. We conducted a systematic review and meta-analysis with the objective of evaluation of the safety and efficacy of LPV/RTV alone or in combination with other drugs with regard to time to becoming PCR negative, time to body temperature normalization and cough relief, radiological progression, and safety. Review Manager (RevMan) was used to conduct all statistical analyses and generate the forest plots. Meta-analyses were performed using the Mantel Hazel method or the inverse variance method for dichotomous data and continuous data respectively.

Non-duplicate articles (n=76) were evaluated for possible inclusion. A consensus was reached to select 29 articles for full-text screening, only 11 articles comprised 1, 192 patients were included in this study, and six of which were included for meta-analysis.

In terms of virological cure (PCR negative), three studies reported less time in days to achieve a virological cure for LPV/RTV arm relative to no antiviral therapy (conventional) (mean difference = −0.81 day; 95% CI, −4.44 to 2.81; P = 0.007, I 2 = 80%). However, the overall effect was not significant (P = 0.66). When comparing LPV/RTV arm to umifenovir arm, a favorable affect was observed for umifenovir arm, but not statically significant (mean difference = 0.95 day; 95% CI, −1.11 to 3.01; P = 0.09, I 2 = 58%).

In terms of time to body normalization and cough relief (clinical cure), two studies reported on time to temperature normalization with no significant effect of LPV/RTV (n = 93) versus umifenovir (n = 71) arm), (OR = 0.87 day; 95% CI, 0.42 to 1.78; (P = 0.70), I2 = 0%), or alleviation of cough duration (p = 0.69).

In terms of CT evidence of radiological progression of pneumonia/lung damage, treatment with lopinavir/ritonavir resulted in no significant decrease in the radiological progression (OR = 0.80; 95% CI, 0.42 to 1.54; P = 0.59, I 2 = 81%), In terms of safety, a greater number of adverse events were reported for lopinavir/ritonavir (n=45) relative to

Since the emergence of an unknown viral infection in China in December 2019 and following the identification of this infection as 2019-new coronavirus disease (2019-nCoV, also known as COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1] , the world is desperate to find effective therapeutics and vaccinations to treat hundred thousand of affected patients and to reduce the spread of this global pandemic [2] .

As June 2, there are 1104 registered clinical trials of COVID-19 therapeutics or vaccinations worldwide that either ongoing or recruiting patients; however, no drug or vaccine has officially been approved for COVID-19 [2, 3]. These trials have produced mixed and conflicting results of positive or negative outcomes and inclusive evidence of efficacy or safety, that render the suspension of some trials inevitable, as in the hydroxychloroquine trials, which was suggested by World Health Organization (WHO) in light of safety concerns [4] . This decision was reversed on June 3, 2020 [5] following a retraction of the research article by Lancet as certain authors were not granted access to the underlying data [6] .

Lopinavir-ritonavir is a protease inhibitor and nucleoside analogue combination used for human immunodeficiency virus (HIV-1), and is also considered a potential treatment for COVID-19 [7] , as its therapeutic value in the treatment of COVID-19 emerged from invitro studies that demonstrated inhibition of several viral corona respiratory illnesses, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 19, 2020. . https://doi.org/10.1101/2020.06. 16.20133298 doi: medRxiv preprint including severe acute respiratory syndrome (SARS-CoV), and Middle East Respiratory Syndrome (MERS) [8. 9, 10] .

Lopinavir (LPV) is an aspartic acid protease inhibitor of HIV, where inhibition of proteases enzymes is essential for the intervening of the viral infectious cycle, and is co-formulated with ritonavir to boost the pharmacokinetic activity and half-life of lopinavir through inhibition of Cytochromes P450, providing adequate suppression of viral load and constant improvements in CD4+ cell counts, as demonstrated in randomized trials in naïve and experienced adults and children HIV patients [7] .

Lopinavir/ritonavir is available as a single-tablet formulation (Kaletra ® ) in dosage strengths of 400/100 mg or 200/100 mg, and in clinical trials, this combination reduced rates of acute respiratory distress syndrome (ARDS) or death compared to supportive care or ribavirin alone in a matched cohort group during the early phase of viral acquisition [8] .

Lopinavir-ritonavir is being examined in several international clinical trials, including the RECOVERY trial and SOLIDARITY WHO trial [11] , but did not gain authorization to be used emergently in the current pandemic in the USA by the Food and Drug Administration (FDA), which has approved only three pharmacologically different therapeutics for treatments of COVID-19, including antibiotic-hydroxychloroquine, immunotherapyconvalescent plasma therapy, and antiviral-remdesivir [2, 11] .

Among the clinical trials that did not find positive results for lopinavir-ritonavir, a study conducted by Bin Cao et al. and published in New England Journal of Medicine [12] revealed that treatment with lopinavir-ritonavir was not associated with clinical The focus of the review was lopinavir/ritonavir treatment in COVID-19 patients. The primary outcome was the efficacy of lopinavir/ritonavir in COVID-19 patients. The secondary outcome was adverse events associated with its use.

Readily accessible peer-reviewed full articles, observational cohort studies, and clinical trials were included.

Participants: Patients with lab-confirmed COVOID-19 of any age were included.

The interventions were lopinavir/ritonavir versus a control of either no antiviral therapy (conventional therapy), standard therapy, or lopinavir/ritonavir with other antiviral agents.

A. Virological cure on day 7 after initiation of therapy (+ve to -ve PCR: non-detection of SARS-CoV-2 in nasopharyngeal swab).

B. Clinical cure (time to body temperature normalization and time to cough relief).

C. Radiological progression during drug treatment.

D. Safety and tolerability of lopinavir/ritonavir.

A. lopinavir/ritonavir vs no antiviral therapy (conventional therapy)/control. B. lopinavir/ritonavir in combination of other agents versus conventional therapy/control. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 19, 2020. . https://doi.org/10.1101/2020.06.16.20133298 doi: medRxiv preprint

The search keywords included 2019-nCoV, 2019 novel coronavirus, COVID-19, coronavirus disease 2019, SARS-COV-2, lopinavir, ritonavir, combination, kaletra, treatment, efficacy, clinical trial, cohort, retrospective, and prospective.

Types of articles that were excluded included duplicate articles, editorials, reviews, case reports, and letters to editors.

Any research articles that did not include data on lopinavir/ritonavir use, did not include control patients' group, or reported combined use of lopinavir/ritonavir with other antiviral medications were also excluded.

Two reviewers (MT and SA) independently screened the titles with abstracts using the selection criteria. For relevant articles, full texts were obtained for further evaluation.

Disagreements between the two reviewers after full text screening were reconciled via consensus by a third reviewer (AA) [19] .

Inclusions and exclusions were recorded following PRISMA guidelines presented in the form of a PRISMA flow diagram and detailed reasons recorded for exclusion. Articles were categorized as clinical trials or cohort studies. The following data were extracted from selected studies: authors; publication year; study location; study design and setting; sample size, age, and gender; details of study intervention and control therapies in addition to data . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 19, 2020. . https://doi.org/10.1101/2020.06. 16.20133298 doi: medRxiv preprint on adverse events and treatment outcomes; assessment of study risk of bias; and remarks on noticeable findings.

The quality assessment of the studies was undertaken based on the revised Cochrane risk of bias tool (RoB 2.0) for randomized controlled studies [20] . ROBINS-I tool was used to asses non-randomized interventional studies [21] , and Newcastle Ottawa Scale for observational cohort studies [22] . Critical appraisal checklists appropriate to each study design were applied and checked by the third-team member.

Three investigators (MT, SA, and AA) separately evaluated the possibility of bias using these tools. Publication bias was not evaluated by funnel plot as there was only three studies which were included in the meta-analysis part of the study.

Statistical heterogeneity was evaluated using the χ 2 test and I 2 statistics (17, 18) . An I 2 value of 0 to <40% was not considered as significant, 30% to 60% was regarded as moderate heterogeneity, 50% to 90% was considered substantial heterogeneity, and 75% to 100% was considered significant heterogeneity.

Because all of the data were continuous and dichotomous data, we used either odds ratio (OR) or mean difference for estimating the point estimate, along with a 95% confidence interval (CI). In the absence of significant clinical heterogeneity, we performed the metaanalysis using the Mantel Hazel method or inverse variance method for dichotomous . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 19, 2020. . https://doi.org/10.1101/2020.06.16.20133298 doi: medRxiv preprint data and continuous data respectively. Employing a conservative approach, a random effects model was used, which produces wider CIs than a fixed effect model [16] .

Review Manager (Version 5.3, Oxford, UK; The Cochrane Collaboration, 2014) was used to conduct all statistical analyses and generate the forest plots [18] .

A total of 8 literature databases were screened and 76 non-duplicate articles was identified, which were evaluated for possible inclusion using titles and abstracts. Out of these, 29 articles were selected for full-text screening and finally, eleven articles (total participants= 1,192) were included in the systematic review and six articles were included in the meta-analysis. 18 articles were excluded following full-text screening (reasons: review= 5, study with no relative data= 6, LPV/RTV use data not available= 2, no control patients in the study= 1, combined LPV/RTV use with other antiviral therapies/other medications data= 2, no extractable data= 2). The PRISMA chart for the included studies is displayed in Figure 1 . The details of the included studies are depicted in Table 1 . Among these, two articles were in preprint versions [23, 24] .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 19, 2020. . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 19, 2020. . Abbreviations: AEs, adverse events; ALT, alanine aminotransferase; COVID-19, coronavirus disease 2019; CT, computed tomography; FiO2, fraction of inspired oxygen; FPV, favipiravir; GI, gastrointestinal; IFN, interferon; IQR, interquartile range; ITT, intention-to-treat; IUs, international units; LOS, length of hospital stay; LPV/RTV, lopinavir/ritonavir; NA, not applicable; NEWS2, National Early Warning Score 2; NHC, National Health Commission of China; NOS, Newcastle Ottawa Scale; PaO2, partial pressure of oxygen; RoB 2, Version 2 of the Cochrane risk-of-bias tool for randomized trials; ROBINS-I, Risk of bias in non-randomized studiesof interventions; RT-PCR, real-time reverse transcription-polymerase chain reaction; SaO2, oxygen saturation; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SCI, subcutaneous injection; SEs, side effects *Standard care comprised, as necessary, supplemental oxygen, noninvasive and invasive ventilation, antibiotic agents, vasopressor support, renal-replacement therapy, and extracorporeal membrane oxygenation (ECMO). is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 19, 2020. . https://doi.org/10.1101/2020.06.16.20133298 doi: medRxiv preprint 2. Lopinavir/ritonavir vs umifenovir: Virologic cure at day 7 post initiation of therapy:

Three studies reported on virological cure (n = 127 in lopinavir/ritonavir alone arm vs n = 87 in umifenovir arm) on day 7 (23, 26, 28) . No significant mean difference was observed between the two arms in terms of virological cure (mean difference = 0.95 day; 95% CI, −1.11 to 3.01; P = 0.09, I 2 = 58%) (Figure 1.2) . is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 19, 2020. . B. Clinical cure (time to body temperature normalization and time to cough relief)

Two studies reported on time to temperature normalization (n = 93 in lopinavir/ritonavir alone arm vs n = 71 in umifenovir arm) [23, 28] . No significant association was observed between the two arms in terms of temperature normalization (OR = 0.87 day; 95% CI, 0.42 to 1.78; P = 0.61, I 2 = 0%) (Figure 1.4) . Two studies reported on cough alleviation (n = 93 in lopinavir/ritonavir alone arm vs n = 71 in umifenovir arm) (23, 28) . Lopinavir/ritonavir alone arm had a significant lower number of cough days by 0.62 (95% CI 0.06 to 6.53, P = 0.02; I 2 = 81%) (Figure 1.6) . is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 19, 2020. .

1. Rate of improvement on chest CT after 7 days of treatment:

In terms of CT evidence of radiological progression of pneumonia/lung damage (n = 59 in the lopinavir/ritonavir arm vs n = 71 in umifenovir arm), treatment with lopinavir/ritonavir resulted in no significant decrease in the radiological progression (OR = 0.80; 95% CI, 0.42 to 1.54; P = 0.59, I 2 = 81%) (Figure 1.8) . compared to the LPV/RTV arm (11.43% vs 55.56%) (p<0.001) (29) . Additionally, no significant difference on average PCR negative conversion times among IFN plus LPV/RTV or IFN plus LPV/RTV plus ribavirin treatment arms [32] .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 19, 2020. 

This systematic review included 11 articles relating to the efficacy and safety of lopinavir/ritonavir in COVID-19 patients, with a total of 1,192 patients included, and only six articles that comprised 594 patients had findings on the efficacy and safety of lopinavir/ritonavir in treatment of COVID-19 verses control/conventional therapy were deemed legible for quantitative synthesis (meta-analysis) [23] [24] [25] [26] [27] [28] .

In terms of virological cure, three studies reported less time in days for LPV/RTV arm (n = 171) compared with no antiviral therapy (conventional) (n= 117); however, the overall effect was not significant (mean difference = −0.81 day; 95% CI, −4.44 to 2.81; P = 0.66), similarly the virological cure for lopinavir/ritonavir alone (n = 127) versus the umifenovir arm (n = 87) (P = 0.37), or lopinavir/ritonavir versus umifenovir plus lopinavir/ritonavir (P = 0.31) [23] [24] [25] [26] [27] [28] .

Two studies reported on time to temperature normalization with no significant effect of LPV/RTV (n = 93) versus umifenovir (n = 71) arm), (OR = 0.87 day; 95% CI, 0.42 to 1.78; (P = 0.70), I2 = 0%), or alleviation of cough duration (p = 0.69) [23, 28] . The total number of cough days was found to be lower in the LPV/RTV arm compared with the umifenovir arm or no antiviral therapy (conventional) arm after 7 days of treatment; however, the overall effect was found to be not significant [23, 28] .

Interestingly in this study, treatment with lopinavir/ritonavir (n = 93) versus umifenovir plus lopinavir/ritonavir (n = 75) arm did not reveal any significant mean difference between the two arms in terms of virological cure at day seven. In contrast, a favorable therapeutic effect for umifenovir was observed in a small cohort study when the drug was combined with lopinavir/ritonavir treatment in sixteen COVID-19 patients rather than lopinavir/ritonavir alone (n=17) [33] .

In another study that involved 81 COVID-19 patients, the umifenovir treatment group had a longer hospital stay than patients in the control group (13 days (IQR 9-17) vs 11 days (IQR 9-14), p 0.04) [34] .

Of note, umifenovir, which is branded as Arbidol®, has a wide antiviral activity against RNA and DNA viruses, and is licensed in Russia and China for treatment and prophylaxis of influenza, is recommended for treatment of MERS-CoV, was investigated in SARS-CoV, and is currently being trialed in COVID-19 patients [35] .

In terms of CT evidence of radiological progression of pneumonia/lung damage of lopinavir/ritonavir arm versus umifenovir, although a fewer number of patients exhibited radiological progression in the LPV/RTV arm compared with the umifenovir arm or no antiviral therapy (conventional) arm after 7 days of treatment, this effect was not significant (P = 0.59). Similarly, with lopinavir/ritonavir (n=71) versus no antiviral therapy [23, 28] .

In terms of safety, this study found greater adverse events reported in lopinavir/ritonavir arm versus no antiviral treatment (conventional) or umifenovir respectively.

Adverse events associated with lopinavir-ritonavir alone or in combination with other medicines were reported in COVID-19 patients, and were typically gastrointestinal (GIT)

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 19, 2020. . https://doi.org/10.1101/2020.06. 16.20133298 doi: medRxiv preprint in nature, including nausea, vomiting, and diarrhea [28]; however, serious GIT ADRs such as acute gastritis and GIT bleeding and acute kidney injury (n=3) were also reported (28). It was reported that most ADRs associated with lopinavir-ritonavir in combined groups of medicines are resolved within three days of drug initiation [29] .

To address the efficacy and safety of LPV/RTV combined with other drugs in patients with COVID-9, LPV/RTV plus IFN combination in addition to ribavirin was found superior and more safe than LPV/RTV alone by shortening time to negative nasopharyngeal swab CT changes compared to the favipiravir plus IFN combination. Favipiravir arm patients had less AEs compared to the LPV/RTV arm [29] . Additionally, there was no significant difference in average PCR negative conversion times among IFN plus LPV/RTV or IFN plus LPV/RTV plus ribavirin treatment arms [32] . The combination of LPV/RTV, in addition to standard care, or standard care alone revealed no difference in the time to clinical improvement with a similar 28-day mortality. Gastrointestinal AEs were more common in the LPV/RTV arm, but serious AEs were more common in the standard care arm and treatment was stopped early in 13.8% of patients because of AEs [12].

In a recent systematic review (preprint version) that included 69 studies which included therapeutics for COVID-19, lopinavir/ritonavir was found to be the third therapeutic associated with positive outcomes (54.9%) with less negative outcomes (12.3%) compared . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 19, 2020. . https://doi.org/10.1101/2020.06. 16.20133298 doi: medRxiv preprint to systemic corticosteroids (21.3%), remdesivir (16.9%), moxioxacin (13.4%) and oseltamivir (12.5%) [36] ; however, further controlled studies are needed to draw a valid conclusion.

The key limitations of this study were the limited number of clinical studies investigating the efficacy and safety of lopinavir/ritonavir combination with the limited number of participants. Another limitation is inability to perform any type of meta-analysis specifically for the results of efficacy and safety of using lopinavir/ritonavir in combination with other agents versus no antiviral therapy (conventional therapy) or control because of the large methodological differences. Despite these limitations, this systematic review provided valuable insight into the efficacy, safety, and clinical outcomes of lopinavir/ritonavir alone or with other antiviral medications.

The small number of studies included in this systematic review and meta-analysis study did not reveal any statistically significant advantage in efficacy of lopinavir-ritonavir in COVID-19 patients, over conventional or other antiviral treatments. In terms of safety, this study found greater number of adverse events reported in lopinavir/ritonavir arm versus no antiviral treatment (conventional) or umifenovir arms respectively.

There is a general understanding of the need to conduct large randomized clinical trials to determine the efficacy and safety of lopinavir-ritonavir in the treatment of COVID-19.

Ideally, these studies should be double-blinded and conducted in a range of settings.

Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city

Therapeutic management of COVID-19 patients: a systematic review

number of coronavirus (COVID-19) clinical trials for drugs and vaccines worldwide as of

Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Trials to resume of anti-viral touted by trump

Lopinavir/ritonavir: a review of its use in the management of HIV infection

Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study

Treatment with Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset

MERS-CoV transmitted from animal-to-human vs MERSCoV transmitted from human-to-human: comparison of virulence and therapeutic outcomes in a Saudi hospital

Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Massachusetts General HospitalCOVID-19 treatment guidance

Saudi Arabia Ministry of Health Coronavirus disease 19 (COVID-19) guidelines, Saudi Arabia Ministry of Health

Health Protection Surveillance Centre Treatment guidelines for COVID-19 in Ireland HPSC

Cochrane handbook for systematic reviews of interventions

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation

Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis

Error rates of human reviewers during abstract screening in systematic reviews

RoB 2: a revised tool for assessing risk of bias in randomised trials

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses

Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial

Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: a pilot retrospective study

Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in patients with SARS-CoV-2 infection

Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19

Efficacies of lopinavir/ritonavir and abidol in the treatment of novel coronavirus pneumonia

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study

Engineering (Beijing)

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019

The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients

Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study

Arbidol (Umifenovir): A Broad-Spectrum Antiviral Drug That Inhibits Medically Important Arthropod-Borne Flaviviruses. Viruses

COVID-19 Therapeutics Outcome: Systematic Review and Data Analysis